{"id":"https://openalex.org/W7204177331","doi":"https://doi.org/10.1186/s12916-026-05154-7","title":"Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial","display_name":"Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial","publication_year":2026,"publication_date":"2026-08-25","ids":{"openalex":"https://openalex.org/W7204177331","doi":"https://doi.org/10.1186/s12916-026-05154-7"},"language":"en","primary_location":{"id":"doi:10.1186/s12916-026-05154-7","doi":"https://doi.org/10.1186/s12916-026-05154-7","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12916-026-05154-7","pdf_url":null,"source":{"id":"https://openalex.org/S135560524","display_name":"BMC Medicine","issn_l":"1741-7015","issn":["1741-7015"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Medicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1186/s12916-026-05154-7","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5121882304","display_name":"Bushu Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210146711","display_name":"Sun Yat-sen University Cancer Center","ror":"https://ror.org/0400g8r85","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210146711"]},{"id":"https://openalex.org/I4391768007","display_name":"State Key Laboratory of Oncology in South China","ror":"https://ror.org/04dn2ax39","country_code":null,"type":"facility","lineage":["https://openalex.org/I157773358","https://openalex.org/I4391768007"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Bushu Xu","raw_affiliation_strings":["Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China","institution_ids":["https://openalex.org/I4210146711","https://openalex.org/I4391768007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067835123","display_name":"Qiuzhong Pan","orcid":"https://orcid.org/0000-0002-2145-535X","observed_orcids":["https://orcid.org/0000-0002-2145-535X"]},"institutions":[{"id":"https://openalex.org/I4210146711","display_name":"Sun Yat-sen University Cancer Center","ror":"https://ror.org/0400g8r85","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210146711"]},{"id":"https://openalex.org/I4391768007","display_name":"State Key Laboratory of Oncology in South China","ror":"https://ror.org/04dn2ax39","country_code":null,"type":"facility","lineage":["https://openalex.org/I157773358","https://openalex.org/I4391768007"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Qiuzhong Pan","raw_affiliation_strings":["Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China","institution_ids":["https://openalex.org/I4210146711","https://openalex.org/I4391768007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004314121","display_name":"Shining Li","orcid":"https://orcid.org/0000-0002-8799-1868","observed_orcids":["https://orcid.org/0000-0002-8799-1868"]},"institutions":[{"id":"https://openalex.org/I4210146711","display_name":"Sun Yat-sen University Cancer Center","ror":"https://ror.org/0400g8r85","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210146711"]},{"id":"https://openalex.org/I4391768007","display_name":"State Key Laboratory of Oncology in South China","ror":"https://ror.org/04dn2ax39","country_code":null,"type":"facility","lineage":["https://openalex.org/I157773358","https://openalex.org/I4391768007"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shining Li","raw_affiliation_strings":["Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China","institution_ids":["https://openalex.org/I4210146711","https://openalex.org/I4391768007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059368310","display_name":"Ruiqing Peng","orcid":"https://orcid.org/0000-0002-5568-103X","observed_orcids":["https://orcid.org/0000-0002-5568-103X"]},"institutions":[{"id":"https://openalex.org/I4210146711","display_name":"Sun Yat-sen University Cancer Center","ror":"https://ror.org/0400g8r85","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210146711"]},{"id":"https://openalex.org/I4391768007","display_name":"State Key Laboratory of Oncology in South China","ror":"https://ror.org/04dn2ax39","country_code":null,"type":"facility","lineage":["https://openalex.org/I157773358","https://openalex.org/I4391768007"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ruiqing Peng","raw_affiliation_strings":["Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China","institution_ids":["https://openalex.org/I4210146711","https://openalex.org/I4391768007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138023107","display_name":"Lihong Zhang","orcid":"https://orcid.org/0000-0003-1296-3237","observed_orcids":["https://orcid.org/0000-0003-1296-3237"]},"institutions":[{"id":"https://openalex.org/I4210160344","display_name":"Tongji Hospital","ror":"https://ror.org/04xy45965","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210160344"]},{"id":"https://openalex.org/I47720641","display_name":"Huazhong University of Science and Technology","ror":"https://ror.org/00p991c53","country_code":"CN","type":"education","lineage":["https://openalex.org/I47720641"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Lihong Zhang","raw_affiliation_strings":["Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China","institution_ids":["https://openalex.org/I4210160344","https://openalex.org/I47720641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148044795","display_name":"Hui Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148548","display_name":"Fujian Provincial Cancer Hospital","ror":"https://ror.org/058ms9w43","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210148548"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Hui Li","raw_affiliation_strings":["Department of Abdominal Medical Oncology, Fujian Cancer Hospital, Fuzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Abdominal Medical Oncology, Fujian Cancer Hospital, Fuzhou, China","institution_ids":["https://openalex.org/I4210148548"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148092262","display_name":"Shiying Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160344","display_name":"Tongji Hospital","ror":"https://ror.org/04xy45965","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210160344"]},{"id":"https://openalex.org/I47720641","display_name":"Huazhong University of Science and Technology","ror":"https://ror.org/00p991c53","country_code":"CN","type":"education","lineage":["https://openalex.org/I47720641"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shiying Yu","raw_affiliation_strings":["Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China","institution_ids":["https://openalex.org/I4210160344","https://openalex.org/I47720641"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113985077","display_name":"Xing Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210146711","display_name":"Sun Yat-sen University Cancer Center","ror":"https://ror.org/0400g8r85","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210146711"]},{"id":"https://openalex.org/I4391768007","display_name":"State Key Laboratory of Oncology in South China","ror":"https://ror.org/04dn2ax39","country_code":null,"type":"facility","lineage":["https://openalex.org/I157773358","https://openalex.org/I4391768007"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xing Zhang","raw_affiliation_strings":["Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma and Sarcoma Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China","institution_ids":["https://openalex.org/I4210146711","https://openalex.org/I4391768007"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5113985077"],"corresponding_institution_ids":["https://openalex.org/I4210146711","https://openalex.org/I4391768007"],"apc_list":{"value":4190,"currency":"USD","value_usd":4190},"apc_paid":{"value":4190,"currency":"USD","value_usd":4190},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.695315,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12278","display_name":"Vascular Tumors and Angiosarcomas","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11638","display_name":"Cardiac tumors and thrombi","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/surufatinib","display_name":"surufatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/advanced-sarcoma","display_name":"advanced sarcoma","score":0.9810000061988831},{"id":"https://openalex.org/keywords/vegfr-inhibition","display_name":"VEGFR inhibition","score":0.7139999866485596},{"id":"https://openalex.org/keywords/fgfr-inhibition","display_name":"FGFR inhibition","score":0.9860000014305115},{"id":"https://openalex.org/keywords/csf1r-inhibition","display_name":"CSF1R inhibition","score":0.9890000224113464},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.859000027179718},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7789999842643738},{"id":"https://openalex.org/keywords/angiosarcoma","display_name":"angiosarcoma","score":0.8889999985694885},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.9150000214576721},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.527999997138977},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4569999873638153},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5709999799728394},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.6919999718666077},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9620000123977661}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9760000109672546},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6959999799728394},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.689300000667572},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5662999749183655},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.5468999743461609},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.5099999904632568},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49889999628067017},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.427700012922287},{"id":"https://openalex.org/C2778629024","wikidata":"https://www.wikidata.org/wiki/Q720020","display_name":"Soft tissue sarcoma","level":3,"score":0.4219000041484833},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.36570000648498535},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.3637000024318695},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36250001192092896},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.35339999198913574},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.3465999960899353},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.3305000066757202},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.32739999890327454},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3203999996185303},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.31209999322891235},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.3050999939441681},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2919999957084656},{"id":"https://openalex.org/C2777532014","wikidata":"https://www.wikidata.org/wiki/Q1504713","display_name":"Leiomyosarcoma","level":2,"score":0.27869999408721924},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.2578999996185303},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.2533000111579895}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1186/s12916-026-05154-7","doi":"https://doi.org/10.1186/s12916-026-05154-7","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12916-026-05154-7","pdf_url":null,"source":{"id":"https://openalex.org/S135560524","display_name":"BMC Medicine","issn_l":"1741-7015","issn":["1741-7015"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1186/s12916-026-05154-7","doi":"https://doi.org/10.1186/s12916-026-05154-7","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12916-026-05154-7","pdf_url":null,"source":{"id":"https://openalex.org/S135560524","display_name":"BMC Medicine","issn_l":"1741-7015","issn":["1741-7015"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.5493754148483276,"display_name":"No poverty","id":"https://metadata.un.org/sdg/1"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G6976922","display_name":null,"funder_award_id":"82272699","funder_id":"https://openalex.org/F4320321001","funder_display_name":"National Natural Science Foundation of China"}],"funders":[{"id":"https://openalex.org/F4320321001","display_name":"National Natural Science Foundation of China","ror":"https://ror.org/01h0zpd94"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Patients":[0,190],"with":[1,48,64,156,168,180,191,228],"advanced,":[2],"treatment-refractory":[3],"sarcoma":[4,50,68],"face":[5],"a":[6,26,154,260,285],"poor":[7],"prognosis":[8],"and":[9,22,41,76,108,158,230,236,259,280],"limited":[10],"options":[11],"following":[12],"failure":[13],"of":[14,24,113,134,234,248],"standard":[15,54],"therapies.":[16],"This":[17],"study":[18],"evaluated":[19],"the":[20,87,117,140,159,277],"efficacy":[21,274],"safety":[23,262],"surufatinib,":[25],"novel":[27],"inhibitor":[28],"targeting":[29],"vascular":[30],"endothelial":[31],"growth":[32,37],"factor":[33,38],"receptor":[34,39,44],"(VEGFR),":[35],"fibroblast":[36],"(FGFR),":[40],"colony-stimulating":[42],"factor-1":[43],"(CSF-1R),":[45],"in":[46,153,246,264,276,281],"patients":[47,63],"advanced":[49,265],"who":[51,69],"had":[52,70,128],"failed":[53],"therapy.":[55,135,271],"In":[56,136],"this":[57],"multicenter,":[58],"single-arm,":[59],"phase":[60],"2":[61,131],"trial,":[62],"unresectable":[65],"or":[66],"metastatic":[67],"received":[71,77,129],"prior":[72,132,269],"treatment":[73],"were":[74],"enrolled":[75,125],"surufatinib":[78,173,254],"300":[79],"mg":[80],"once":[81],"daily.":[82],"The":[83,145,272],"primary":[84],"endpoint":[85],"was":[86,120,143,147,161,165,174,225],"12-week":[88],"progression-free":[89,105],"rate":[90,99,103],"(PFR":[91],"12w":[92,142],").":[93],"Secondary":[94],"endpoints":[95],"included":[96],"objective":[97],"response":[98,152],"(ORR),":[100],"disease":[101],"control":[102],"(DCR),":[104],"survival":[106,110],"(PFS),":[107],"overall":[109],"(OS).":[111],"As":[112],"September":[114],"30,":[115],"2025,":[116],"median":[118],"follow-up":[119],"27.5":[121],"months":[122],"among":[123],"47":[124],"patients;":[126],"46.8%":[127],"\u2265":[130,240],"lines":[133,182],"45":[137],"evaluable":[138],"patients,":[139],"PFR":[141],"71.1%.":[144],"ORR":[146],"11.1%,":[148],"including":[149],"one":[150],"complete":[151],"patient":[155],"angiosarcoma,":[157],"DCR":[160],"86.7%.":[162],"Median":[163,223],"PFS":[164,171,197,214],"4.3":[166,218],"months,":[167],"significantly":[169],"longer":[170],"when":[172],"used":[175],"as":[176],"second-line":[177,278],"therapy":[178,210],"compared":[179],"later":[181],"(5.7":[183],"vs.":[184,217],"2.8":[185],"months;":[186,202,219],"p":[187,203,220],"<":[188],"0.001).":[189],"non-uterine":[192,282],"leiomyosarcoma":[193,283],"also":[194],"showed":[195],"improved":[196],"(median:":[198,215],"7.2":[199],"vs":[200],"4.2":[201],"=":[204,221],"0.024).":[205],"Prior":[206],"exposure":[207],"to":[208],"anti-angiogenic":[209,270],"did":[211],"not":[212,226],"impact":[213],"3.3":[216],"0.924).":[222],"OS":[224,232],"reached,":[227],"1-":[229],"2-year":[231],"rates":[233],"82.2%":[235],"63.9%,":[237],"respectively.":[238],"Grade":[239],"3":[241],"treatment-related":[242],"adverse":[243],"events":[244],"occurred":[245],"29.8%":[247],"patients.":[249],"These":[250],"findings":[251],"indicate":[252],"that":[253],"has":[255],"preliminary":[256],"antitumor":[257],"activity":[258],"manageable":[261],"profile":[263],"sarcoma,":[266],"even":[267],"after":[268],"encouraging":[273],"observed":[275],"setting":[279],"provides":[284],"rationale":[286],"for":[287],"continued":[288],"clinical":[289],"development.":[290],"ClinicalTrials.gov:":[291],"NCT05106777.":[292],"ClinicalTrials.gov":[293],"(":[294],"http://www.clinicaltrials.gov/":[295],")":[296]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2026-08-26T00:00:00"}